Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000932471-25-001050
Filing Date
2025-07-29
Accepted
2025-07-29 14:40:47
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4686
  Complete submission text file 0000932471-25-001050.txt   6483
Mailing Address PO BOX 2600 V26 VALLEY FORGE PA 19482-2600
Business Address 100 VANGUARD BLVD MALVERN PA 19355 6106691000
VANGUARD GROUP INC (Filed by) CIK: 0000102909 (see all company filings)

EIN.: 231945930 | State of Incorp.: PA | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89456 | Film No.: 251160677
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)